Extracorporeal membrane oxygenation versus invasive ventilation in patients with COVID ‐19 acute respiratory distress syndrome and pneumomediastinum: A cohort trial
Artificial Organs · 2024
DOI: 10.1111/aor.14760 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Artificial Organs, 2024. Verfasst von Rachid Attou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Intensive Care, Brugmann University Hospital, Université Libre de Bruxelles, Brussels, Belgium. Hauptthemen laut MEDLINE: Extracorporeal Membrane Oxygenation, COVID-19, Mediastinal Emphysema, Respiration, Artificial. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Background
Patients with severe respiratory failure due to COVID‐19 who are not under mechanical ventilation may develop severe hypoxemia when complicated with spontaneous pneumomediastinum (PM). These patients may be harmed by invasive ventilation. Alternatively, veno‐venous (V‐V) extracorporeal membrane oxygenation (ECMO) may be applied. We report on the efficacy of V‐V ECMO and invasive ventilation as initial advanced respiratory support in patients with COVID‐19 and acute respiratory failure due to spontaneous PM.
Methods
This was a retrospective cohort study performed between March 2020 and January 2022. Enrolled patients had COVID‐19 and acute respiratory failure due to spontaneous PM and were not invasively ventilated. Patients were treated in the intensive care unit (ICU) with invasive ventilation (invasive ventilation group) or V‐V ECMO support (V‐V ECMO group) as the main therapeutic option. The primary outcomes were mortality and ICU discharge at 90 days after ICU admission.
Results
Twenty‐two patients were included in this study (invasive ventilation group: 13 [59%]; V‐V ECMO group: 9 [41%]). The V‐V ECMO strategy was significantly associated with lower mortality (hazard ratio [HR] 0.33 [95% CI 0.12–0.97], p = 0.04). Five (38%) patients in the V‐V ECMO group were intubated and eight (89%) patients in the invasive ventilation group required V‐V ECMO support within 30 days from ICU admission. Three (33%) patients in the V‐V ECMO group were discharged from ICU within 90 days compared to one (8%) patient in the invasive ventilation group (HR 4.71 [95% CI 0.48–45.3], p = 0.18).
Conclusions
Preliminary data suggest that V‐V ECMO without invasive ventilation may improve survival in COVID‐19‐related acute respiratory failure due to spontaneous PM. The study's retrospective design and limited sample size underscore the necessity for additional investigation and warrant caution.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Intensive Care, Brugmann University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
- Department of Internal Medicine, University Hospital of Patras, Patras, Greece.
ORCID-Profile: Rachid Attou, Sebastien Redant, Dimitrios Velissaris, Keitiane Kefer, Charalampos Pierrakos
Zitieren
APA
Attou, R., Redant, S., Velissaris, D., Kefer, K., Abou Lebdeh, M., Waterplas, E., & Pierrakos, C. (2024). Extracorporeal membrane oxygenation versus invasive ventilation in patients with COVID ‐19 acute respiratory distress syndrome and pneumomediastinum: A cohort trial. Artificial Organs. https://doi.org/10.1111/aor.14760
Vancouver
Attou R, Redant S, Velissaris D, Kefer K, Abou Lebdeh M, Waterplas E, et al. Extracorporeal membrane oxygenation versus invasive ventilation in patients with COVID ‐19 acute respiratory distress syndrome and pneumomediastinum: A cohort trial. Artificial Organs. 2024. doi:10.1111/aor.14760
BibTeX
@article{Attou2024,
author = {Attou, Rachid and Redant, Sebastien and Velissaris, Dimitrios and Kefer, Keitiane and Abou Lebdeh, Mazen and Waterplas, Eric and Pierrakos, Charalampos},
title = {Extracorporeal membrane oxygenation versus invasive ventilation in patients with COVID ‐19 acute respiratory distress syndrome and pneumomediastinum: A cohort trial},
journal = {Artificial Organs},
year = {2024},
doi = {10.1111/aor.14760}
}
EUVIMED